A Phase 4 interventional study of ADVAIR 100/50mcg and ADVAIR 250/50mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 808 sites in 33 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-08-06.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one has the largest enrollment of the 146 interventional ones that give a count, is one of 8 that started in 2011, is one of 52 in phase 4, and was the 82nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11,751 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one has the largest enrollment of the 238 interventional ones that give a count, is one of 14 that started in 2011, is one of 53 in phase 4, and was the 138th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.
ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.
Progress of Enrollment, Updated Annually: This study has been completed and the final clinical study report was submitted to the FDA in January of 2016. This is the final update, as this study is complete.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
experimental drug
Drug: ADVAIR 100/50mcg
experimental drug
Drug: ADVAIR 250/50mcg
experimental drug
Drug: ADVAIR 500/50mcg
active comparator
Drug: FLOVENT 100mcg
active comparator
Drug: FLOVENT 250mcg
active comparator
Drug: FLOVENT 500mcg
fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Also known as: FSC 100/50
fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Also known as: FSC 250/50
fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
Also known as: FSC 500/50
fluticasone propionate (100) twice daily (AM and PM) for 6 months
Also known as: FP 100
fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Also known as: FP 250
fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
Also known as: FP 500
Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)
Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility. Probability of having event was summarized with Kaplan-Meier estimates.Hazard ratio, confidence interval, and p-value are from a stratified Cox proportional hazard model, using randomization stratum as the stratification factor. The 95% CI provided in the table is actually the 95.
Time frame: From Day 1 up to 26 weeks
Number of Participants Experiencing at Least One Asthma Exacerbation
An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
Time frame: From Day 1 up to 26 weeks
Number of Participants Experiencing at Least One Asthma Related Hospitalization , Endotracheal Intubation and Death
Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility.
Time frame: From Day 1 up to 26 weeks
Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation
An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
Time frame: From Day 1 up to 26 weeks
Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours
Rescue medication included albuterol/salbutamol used to treat acute asthma were reported as puffs per 24 hours over a period of 6 months.
Time frame: From Day 1 up to 26 weeks
Study duration was 29 weeks, comprised of a randomization visit followed by a treatment period of 26 weeks and a 1 week follow-up phone call. Participants were assessed for eligibility at screening up to 15 days prior to randomization.
| Milestone | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| Started | 5834 | 5845 |
| Completed | 5823 | 5831 |
| Not completed | 11 | 14 |
| Withdrew: Death | 3 | 6 |
| Withdrew: Withdrawal by subject | 8 | 8 |
Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility. Probability of having event was summarized with Kaplan-Meier estimates.Hazard ratio, confidence interval, and p-value are from a stratified Cox proportional hazard model, using randomization stratum as the stratification factor. The 95% CI provided in the table is actually the 95.
| Participants | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death) | 34 | 33 |
An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
| Participants | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| Number of Participants Experiencing at Least One Asthma Exacerbation | 480 | 597 |
Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility.
| Participants | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| Hospitalization | 34 | 33 |
| Endotracheal intubation | 0 | 2 |
| Death | 0 | 0 |
An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
| Participants | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation | 66 | 84 |
Rescue medication included albuterol/salbutamol used to treat acute asthma were reported as puffs per 24 hours over a period of 6 months.
| Number of Puffs | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours | 0.90 ± 0.018 | 1.09 ± 0.020 |
Collected over Serious adverse events (SAEs) and non-serious events (AEs) were collected from post-randomization, throughout the treatment period of 26 weeks up to a 1-week follow-up phone call (27 Weeks).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Propionate/Salmeterol Combination (FSC) | — | 134/5,834 (2.3%) | 46/5,834 (0.8%) |
| Fluticasone Propionate (FP) | — | 125/5,845 (2.1%) | 75/5,845 (1.3%) |
| Event | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 30/5834 | 28/5845 |
| PneumoniaInfections and infestations | 8/5834 | 8/5845 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/5834 | 5/5845 |
| Cerebrovascular accidentNervous system disorders | 4/5834 | 3/5845 |
| Chest painGeneral disorders | 2/5834 | 4/5845 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/5834 | 4/5845 |
| AnaemiaBlood and lymphatic system disorders | 3/5834 | 1/5845 |
| Atrial fibrillationCardiac disorders | 3/5834 | 0/5845 |
| PyelonephritisInfections and infestations | 3/5834 | 0/5845 |
| Diabetes mellitusMetabolism and nutrition disorders | 3/5834 | 0/5845 |
| Event | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 46/5834 | 75/5845 |
| Age, Continuous(Years) | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) | Total |
|---|---|---|---|
| Mean | 43.4 ± 17.45 | 43.4 ± 17.28 | 43.4 ± 17.36 |
| Sex: Female, Male(Participants) | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) | Total |
|---|---|---|---|
| Female | 3851 | 3898 | 7749 |
| Male | 1983 | 1947 | 3930 |
| Race/Ethnicity, Customized(Participants) | Fluticasone Propionate/Salmeterol Combination (FSC) | Fluticasone Propionate (FP) | Total |
|---|---|---|---|
| Missing | 3 | 3 | 6 |
| African American/African Heritage | 870 | 856 | 1726 |
| American Indian/Alaska native | 109 | 116 | 225 |
| Asian-Central/South Asian Heritage | 36 | 45 | 81 |
| Asian-East Asian Heritage | 94 | 88 | 182 |
| Japanese Heritage | 4 | 3 | 7 |
| Asian-South East Asian Heritage | 234 | 224 | 458 |
| Native Hawaiian or other Pacific Islander | 8 | 10 | 18 |
| White-Arabic/North African Heritage | 22 | 21 | 43 |
| White-White/Caucasian/European Heritage | 4352 | 4388 | 8740 |
| Multiple | 102 | 91 | 193 |
Showing the first 100 of 808 sites across 33 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Nov 2011 to primary completion in Jun 2015, 43 months.
Results were first posted in Jan 2016, 6 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 43 months is above that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone